The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Therapeutic advances improving surgical outcomes for metastatic disease
Elena Prisciandaro, MD, University Hospitals Leuven, Leuven, Belgium, talks on advances in therapeutics improving survival of patients with metastatic disease undergoing surgery, including immunotherapies, chemotherapies and radiotherapies. Developments in personalized medicine will further improve surgical outcomes for lung cancer, as well as for metastatic disease. This interview took place during the virtual European Lung Cancer Congress 2022.
